Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol

 
• By Mandy Jackson

Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.

Diagnosis of Myelofibrosis. Laboratory blood bottle (tube), glass slide with blood smear, hematology test, stethoscope lying on notebook with printed text hematological diagnosis of Myelofibrosis - Image
Inrebic is only the second drug, after Jakafi, approved for myelofibrosis in the US. • Source: Shutterstock

More from New Products

More from Scrip